R&G PharmaStudies Co., Ltd. (SHE:301333)

China · Delayed Price · Currency is CNY

49.92

+0.87 (1.77%)

At close: Jun 23, 2026

13.38% (1Y)

Market Cap	4.71B +2.1%
Revenue (ttm)	896.26M +21.2%
Net Income	133.65M -6.7%
EPS	1.40 -6.5%
Shares Out	95.99M
PE Ratio	35.00
Forward PE	28.35
Dividend	0.16 (0.34%)
Ex-Dividend Date	Jul 8, 2025

Volume	3,429,935
Open	48.80
Previous Close	49.05
Day's Range	48.58 - 51.74
52-Week Range	43.50 - 91.78
Beta	0.37
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About R&G PharmaStudies

R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It offers drug clinical research and development integrated services. The company’s services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology services. It serves pharmaceutical and medical device companies, and scientific research institutions. The company was founded in 2008 and is headquarter... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2008

Employees 2,645

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 301333

Full Company Profile

Financial Performance

In 2025, R&G PharmaStudies's revenue was 851.01 million, an increase of 14.38% compared to the previous year's 744.00 million. Earnings were 136.90 million, a decrease of -2.37%.

Financial Statements